Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Mongraw-Chaffin M, Foster MC, Anderson CAM, et al
Nooms app is where you complete all tasks
In May 2025, CVS Caremark announced that anti-obesity (AOM) tirzepatide (sold as Zepbound) would be removed from its preferred formulary effective July 1, 2025, with AOM semaglutide (sold as Wegovy) designated as the preferred alternative
No third-party batch reports have been uploaded for this product yet
US$ 26.95
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 26.72
US$ 27.59
,type=downsize)
